Free Trial

ARS Pharmaceuticals Q2 2023 Earnings Report

ARS Pharmaceuticals logo
$11.24 -0.54 (-4.58%)
As of 04:00 PM Eastern

ARS Pharmaceuticals EPS Results

Actual EPS
-$0.18
Consensus EPS
-$0.17
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

ARS Pharmaceuticals Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

ARS Pharmaceuticals Announcement Details

Quarter
Q2 2023
Time
N/A

ARS Pharmaceuticals Earnings Headlines

A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
ARS Pharmaceuticals initiated with an Outperform at Oppenheimer
See More ARS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like ARS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ARS Pharmaceuticals and other key companies, straight to your email.

About ARS Pharmaceuticals

ARS Pharmaceuticals (NASDAQ:SPRY), a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

View ARS Pharmaceuticals Profile

More Earnings Resources from MarketBeat